Pharmaceutical fund managers are mirroring the strategy used in the new energy vehicle sector by investing in upstream suppliers for innovative drugs, specifically focusing on experimental animals like rhesus monkeys and mice. This approach aims to mitigate the high investment and failure risks associated with direct drug development, instead capitalizing on the consistent demand and strong cash flow of research service providers. The market anticipates a dual improvement in performance and valuation for this sector, driven by the increasing importance of clinical data in assessing drug pipeline value. AI
IMPACT This investment strategy shift in pharma could lead to increased demand and innovation in AI-driven drug discovery and research tools.
RANK_REASON The article discusses a shift in investment strategy within the pharmaceutical sector, focusing on upstream suppliers and experimental animals, which represents a significant industry move. [lever_c_demoted from significant: ic=1 ai=0.4]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
